Loading clinical trials...
Loading clinical trials...
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.
This is an open label trial. The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide in the treatment of acute attacks of hereditary angioedema. This study is designed to provide efficacy and safety data on repeated use of ecallantide. These data are intended to support the marketing authorization of ecallantide in the treatment of acute attacks of hereditary angioedema. Efficacy and safety of ecallantide will be evaluated in this study.
Age
10 - No limit years
Sex
ALL
Healthy Volunteers
No
Aaron Davis
Scottsdale, Arizona, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas, United States
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States
Pacific Coast Allergy
Crescent City, California, United States
Jacob Offenberger
Granada Hills, California, United States
UCLA David Geffen School of Medicine, Department of Medicine
Los Angeles, California, United States
Asthma and Allergy Associates, P.C.
Colorado Springs, Colorado, United States
Christiana Hospital, Christiana Care Health Services
Newark, Delaware, United States
Georgetown University Medical Center, Georgetown University Hospital
Washington D.C., District of Columbia, United States
Start Date
April 1, 2007
Primary Completion Date
June 1, 2010
Completion Date
September 1, 2010
Last Updated
June 8, 2021
147
ACTUAL participants
ecallantide
DRUG
Lead Sponsor
Shire
NCT07298447
NCT06842823
NCT05469789
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions